These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10632318)

  • 1. Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect.
    Kopelovich L; Henson DE; Gazdar AF; Dunn B; Srivastava S; Kelloff GJ; Greenwald P
    Clin Cancer Res; 1999 Dec; 5(12):3899-905. PubMed ID: 10632318
    [No Abstract]   [Full Text] [Related]  

  • 2. [Geomagnetic field variation in early ontogenesis as a risk factor for oncopathology].
    Iamshanov VA
    Vopr Onkol; 2003; 49(5):608-11. PubMed ID: 14682133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organ- and tissue-specific stem cells and carcinogenesis.
    Pathak S
    Anticancer Res; 2002; 22(3):1353-6. PubMed ID: 12168810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of familial history and smoking on common cancer risks in Japan.
    Suzuki T; Matsuo K; Wakai K; Hiraki A; Hirose K; Sato S; Ueda R; Tajima K
    Cancer; 2007 May; 109(10):2116-23. PubMed ID: 17410537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age.
    Zacharatou Jarlskog C; Paganetti H
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):228-35. PubMed ID: 18571337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of cancer risk due to stochastic effects.
    Heidenreich WF
    Risk Anal; 2005 Dec; 25(6):1589-94. PubMed ID: 16506984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological evaluation of cytogenetic biomarkers as potential surrogate end-points for cancer.
    Hagmar L; Strömberg U; Tinnerberg H; Mikoczy Z
    IARC Sci Publ; 2004; (157):207-15. PubMed ID: 15055297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Environmental and hereditary factors in the causation of cancer].
    Bonaït-Pellié C
    Rev Epidemiol Sante Publique; 2000 Dec; 48(6):589-90. PubMed ID: 11386211
    [No Abstract]   [Full Text] [Related]  

  • 9. Attributable risks of familial cancer from the Family-Cancer Database.
    Hemminki K; Czene K
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1638-44. PubMed ID: 12496055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correspondence Re: Farber E: Cell proliferation is not a major risk factor for cancer. Mod Pathol 9:606, 1996.
    O'Connell JT
    Mod Pathol; 1996 Nov; 9(11):1092-3. PubMed ID: 8933524
    [No Abstract]   [Full Text] [Related]  

  • 11. Correspondence Re: Farber E: Cell proliferation is not a major risk factor for cancer. Mod Pathol 9:606, 1996.
    Morris SA
    Mod Pathol; 1996 Nov; 9(11):1094-5. PubMed ID: 8933525
    [No Abstract]   [Full Text] [Related]  

  • 12. Dietary patterns and risk of cancer of various sites in the Norwegian European Prospective Investigation into Cancer and Nutrition cohort: the Norwegian Women and Cancer study.
    Engeset D; Dyachenko A; Ciampi A; Lund E
    Eur J Cancer Prev; 2009 Feb; 18(1):69-75. PubMed ID: 19077568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aneuploidy-selected paternal vs. maternal genome contribute to the malignant phenotype of cancer.
    Zhang F; Zhao D; Li Q
    Med Hypotheses; 2006; 67(6):1468-9. PubMed ID: 16860941
    [No Abstract]   [Full Text] [Related]  

  • 14. Interrogating DNA repair in cancer risk assessment.
    Paz-Elizur T; Brenner DE; Livneh Z
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1585-7. PubMed ID: 16030087
    [No Abstract]   [Full Text] [Related]  

  • 15. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study.
    Hassan MM; Phan A; Li D; Dagohoy CG; Leary C; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):959-65. PubMed ID: 18398037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer genetics.
    Ponder BA
    Nature; 2001 May; 411(6835):336-41. PubMed ID: 11357140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle.
    Davis S; Mirick DK
    Cancer Causes Control; 2006 May; 17(4):539-45. PubMed ID: 16596308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan.
    Inoue M; Noda M; Kurahashi N; Iwasaki M; Sasazuki S; Iso H; Tsugane S;
    Eur J Cancer Prev; 2009 Jun; 18(3):240-7. PubMed ID: 19491612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hedgehog signaling pathway and its impact on development of cancer therapy].
    Nakamura M; Katano M
    Fukuoka Igaku Zasshi; 2008 May; 99(5):102-6. PubMed ID: 18788453
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer stem cells--old concepts, new insights.
    Vermeulen L; Sprick MR; Kemper K; Stassi G; Medema JP
    Cell Death Differ; 2008 Jun; 15(6):947-58. PubMed ID: 18259194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.